Amicus Therapeutics (FOLD) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Amicus Therapeutics (FOLD) PT Lowered to $14 at BofA Securities
February 19, 2025 1:48 PM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $14.00 (from $15.00) while maintaining a Buy rating.
The analyst comments "Amicus Therapeutics (FOLD, Buy, $14 PO) announced FY24 total revenue of $528.3mn (33% y/y), Galafold of $458.2mn (y/y... More
